<SEC-DOCUMENT>0001206774-14-002580.txt : 20140819
<SEC-HEADER>0001206774-14-002580.hdr.sgml : 20140819
<ACCEPTANCE-DATETIME>20140819163030
ACCESSION NUMBER:		0001206774-14-002580
CONFORMED SUBMISSION TYPE:	SC 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20140819
DATE AS OF CHANGE:		20140819

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Asterias Biotherapeutics, Inc.
		CENTRAL INDEX KEY:			0001572552
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461047971
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-87639
		FILM NUMBER:		141052413

	BUSINESS ADDRESS:	
		STREET 1:		230 CONSTITUTION DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		510-521-3390

	MAIL ADDRESS:	
		STREET 1:		230 CONSTITUTION DRIVE
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GERON CORP
		CENTRAL INDEX KEY:			0000886744
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				752287752
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SC 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025
		BUSINESS PHONE:		6504737700

	MAIL ADDRESS:	
		STREET 1:		149 COMMONWEALTH DRIVE
		STREET 2:		SUITE 2070
		CITY:			MENLO PARK
		STATE:			CA
		ZIP:			94025

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	GERON CORPORATION
		DATE OF NAME CHANGE:	19960521
</SEC-HEADER>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>geron_sc13da.htm
<DESCRIPTION>AMENDMENT TO SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP
<TEXT>

<HTML>
<HEAD>
   <TITLE></TITLE>
</HEAD>

<BODY bgcolor=#ffffff>
<BR>
<P align=center><B><FONT face="Times New Roman">UNITED
STATES<BR></FONT></B><B><FONT face="Times New Roman">SECURITIES AND EXCHANGE
COMMISSION<BR>Washington, D.C. 20549 </FONT></B></P>
<P align=center><B><FONT face="Times New Roman">_____________ </FONT></B></P>
<P align=center><B><FONT face="Times New Roman" size=4>SCHEDULE
13D/A</FONT></B><B><FONT face="Times New Roman"> </FONT></B></P>
<P align=center><B><FONT face="Times New Roman">Under the Securities Exchange
Act of 1934<BR>(Amendment No. 2)* </FONT></B></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="100%"><FONT face="Times New Roman" size=2>Asterias Biotherapeutics, Inc.</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>(Name of Issuer)</FONT></TD></TR>
  <TR>
    <TD width="100%">&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="100%"><FONT face="Times New Roman" size=2>Series A Common Stock, par value
      $0.0001 per share</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>(Title of Class of Securities)</FONT></TD></TR>
  <TR>
    <TD width="100%">&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="100%"><FONT face="Times New Roman" size=2>04624N 107</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>(CUSIP Number)</FONT></TD></TR></TABLE><BR>
<P align=center><FONT face="Times New Roman" size=2>Geron Corporation<BR>Olivia
K. Bloom<BR></FONT><FONT face="Times New Roman" size=2>Executive Vice President,
Finance, Chief Financial Officer and Treasurer<BR>149 Commonwealth Drive, Suite
2070<BR>Menlo Park, California 94025<BR>(650) 473-7700 </FONT></P>
<P align=center><FONT face="Times New Roman" size=2>Copies To: </FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>Chadwick L. Mills</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>Cooley LLP</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>3175
      Hanover Street</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>Palo
      Alto, California 94304</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=center width="100%"><FONT face="Times New Roman" size=2>(650) 843-5000</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>(Name, Address and Telephone Number of
      Person</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>Authorized to Receive Notices and
      Communications)</FONT></TD></TR>
  <TR>
    <TD width="100%">&nbsp;&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" align=center width="100%"><FONT face="Times New Roman" size=2>August 15, 2014</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap style="text-align: center" width="100%"><FONT face="Times New Roman" size=2>(Date of Event which Requires Filing of this
      Statement)</FONT></TD></TR></TABLE><BR>
<P align=left><FONT face="Times New Roman" size=2>If the filing person has
previously filed a statement on Schedule 13G to report the acquisition that is
the subject of this Schedule 13D, and is filing this schedule because of Rule
13d-1(e), 13d-1(f) or 13d-1(g), check the following box __.</FONT></P>
<P align=left><B><FONT face="Times New Roman" size=2>Note: </FONT></B><FONT face="Times New Roman" size=2>Schedules filed in paper format shall include a
signed original and five copies of the schedule, including all exhibits. See
Rule 13d-7 for other parties to whom copies are to be sent.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>*The remainder of this cover
page shall be filled out for a reporting person&#146;s initial filing on this form
with respect to the subject class of securities, and for any subsequent
amendment containing information which would alter disclosures provided in a
prior cover page.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The information required on
the remainder of this cover page shall not be deemed to be "filed" for the
purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or
otherwise subject to the liabilities of that section of the Act but shall be
subject to all other provisions of the Act (however, see the Notes).</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman">SCHEDULE 13D/A</FONT></B></P>
<TABLE style="PADDING-RIGHT: 4pt; PADDING-LEFT: 4pt; PADDING-BOTTOM: 4pt; LINE-HEIGHT: 14pt; PADDING-TOP: 4pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="25%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="100%"><B><FONT face="Times New Roman" size=2>CUSIP No. 04624N 107</FONT></B></TD></TR></TABLE><BR>
<TABLE style="PADDING-LEFT: 4pt; LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>1</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-TOP: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Name of Reporting Persons.&nbsp;&nbsp; I.R.S. Identification Nos.
      of above persons (entities only).</FONT></TD></TR>
  <TR style="LINE-HEIGHT: 5pt">
    <TD style="BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><B><FONT face="Times New Roman" size=2>G</FONT></B><B><FONT face="Times New Roman" size=1>ERON </FONT></B><B><FONT face="Times New Roman" size=2>C</FONT></B><B><FONT face="Times New Roman" size=1>ORPORATION</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>I.R.S. Identification No.:
      </FONT><B><FONT face="Times New Roman" size=2>75-2287752</FONT></B></TD></TR>
  <TR style="LINE-HEIGHT: 5pt">
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>2</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Check the Appropriate Box if
      a Member of a Group (See Instructions)</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>(a) <FONT face=Wingdings>&#168;</FONT><FONT face="Times New Roman" size=2></FONT></FONT></TD></TR>
  <TR style="LINE-HEIGHT: 5pt">
    <TD style="BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>(b) <FONT face=Wingdings>&#168;</FONT></FONT></TD></TR>
  <TR style="LINE-HEIGHT: 5pt">
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>&nbsp;</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>3</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>SEC Use Only</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>4</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Source of Funds (See Instructions) </FONT><B><FONT face="Times New Roman" size=2>OO</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>5</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Check if Disclosure of Legal Proceedings Is Required Pursuant to
      Items 2(d) or
      2(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <FONT face=Wingdings>&#168;</FONT><FONT face="Times New Roman" size=2></FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>6</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Citizenship or Place of
      Organization&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT><B><FONT face="Times New Roman" size=2>D</FONT></B><B><FONT face="Times New Roman" size=1>ELAWARE</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%" rowSpan=4><FONT face="Times New Roman" size=2>&nbsp; Number of<BR>&nbsp; Shares?<BR>&nbsp; Beneficially<BR>&nbsp;
      Owned by<BR>&nbsp; Each<BR>&nbsp; Reporting<BR>&nbsp; Person<BR>&nbsp;
      With</FONT></TD>
    <TD noWrap align=left width="3%"></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>7</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Sole Voting Power</FONT>&nbsp;<FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B><FONT face="Times New Roman">0</FONT></B></FONT> <B><FONT face="Times New Roman" size=2><SUP></SUP></FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="3%"></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="3%"><STRONG><FONT face="Times New Roman" size=2>8</FONT></STRONG></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Shared Voting
      Power&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B><FONT face="Times New Roman">0</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="3%"></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>9</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Sole Dispositive
      Power&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman">0</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"></TD>
    <TD style="BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="3%"><STRONG><FONT face="Times New Roman" size=2>10&nbsp;&nbsp;&nbsp;&nbsp;
    </FONT></STRONG></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; BORDER-LEFT: #000000 1pt solid; BORDER-BOTTOM: #000000 1pt solid" vAlign=middle noWrap align=left width="90%"><FONT face="Times New Roman" size=2>Shared Dispositive
      Power&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT><FONT face="Times New Roman" size=2><B><FONT face="Times New Roman">0</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>11</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Aggregate Amount Beneficially Owned by Each Reporting
      Person&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      </FONT><B><FONT face="Times New Roman" size=2>0</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>12</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Check if the Aggregate Amount in Row (11) Excludes Certain Shares
      (See
      Instructions)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
      <FONT face=Wingdings>x</FONT><FONT face="Times New Roman"><STRONG><SUP>(1)</SUP></STRONG></FONT></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>13</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Percent of Class Represented by Amount in Row
      (11)</FONT>&nbsp;<FONT face="Times New Roman" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <B><FONT face="Times New Roman">0%</FONT></B></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; BORDER-LEFT: #000000 1pt solid; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" vAlign=top noWrap align=left width="3%"><B><FONT face="Times New Roman" size=2>14</FONT></B></TD>
    <TD style="BORDER-RIGHT: #000000 1pt solid; PADDING-BOTTOM: 8pt; PADDING-TOP: 8pt; BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="96%" colSpan=3><FONT face="Times New Roman" size=2>Type of Reporting Person (See
      Instructions)<BR>
      </FONT><B><FONT face="Times New Roman" size=2>CO</FONT></B></TD></TR></TABLE>____________________<BR>&nbsp;<BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=1>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=1>Excludes
      any shares of Series A common stock, par value $0.0001 per share (&#147;Series
      A Common Stock&#148;), of Asterias Biotherapeutics, Inc. beneficially owned by
      the executive officers and directors of Geron Corporation.</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman">SCHEDULE 13D/A</FONT></B><FONT face="Times New Roman" size=1> </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>This Amendment No. 2 on
Schedule 13D/A (the &#147;Amendment&#148;) amends and supplements the Schedule 13D
originally filed with the U.S. Securities and Exchange Commission on October 9,
2013, and as amended on May 28, 2014 (the &#147;Geron Schedule 13D&#148;), by Geron
Corporation, a Delaware corporation (the &#147;Reporting Person&#148; or
&#147;Geron&#148;).</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Capitalized terms not defined
herein have the meanings given to such terms in the Geron Schedule 13D. Unless
set forth below, all previous Items set forth in the Geron Schedule 13D are
unchanged. This Amendment is being filed to amend and supplement Item 2, Item 4
and Item 5 of the Geron Schedule 13D as set forth below. This Amendment is also
the final amendment to the Geron Schedule 13D and an exit filing for the
Reporting Person.</FONT></P>
<P align=left><B><FONT face="Times New Roman">Item 2 - Identity and Background
</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>The information contained in
Item 2 of the Geron Schedule 13D is hereby amended and supplemented by adding
the following information:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>Schedule I attached hereto is
incorporated herein by reference and amends and restates Schedule I of the Geron
Schedule 13D in its entirety. All of the directors and executive officers of
Geron named in Schedule I to this Amendment are citizens of the United States.
During the last five years, neither the Reporting Person nor, to the knowledge
of the Reporting Person, any of the directors or executive officers identified
on Schedule I to this Amendment: (i) has been convicted in any criminal
proceeding (excluding traffic violations or similar misdemeanors) or (ii) was a
party to a civil proceeding of a judicial or administrative body of competent
jurisdiction and as a result of such proceeding was or is subject to a judgment,
decree or final order enjoining future violations of, or prohibiting or
mandating activities subject to, U.S. federal or state securities laws or
finding any violation with respect to such laws.</FONT></P>
<P align=left><B><FONT face="Times New Roman">Item 4 - Purpose of
Transaction</FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>The information contained in
Item 4 of the Geron Schedule 13D is hereby amended and supplemented by adding
the following information:</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>On August 15, 2014, the
Reporting Person completed the Series A Distribution, and the Reporting Person
no longer holds any shares of Series A Common Stock. The Series A Distribution
was effected by means of a distribution to Geron&#146;s stockholders, on a pro rata
basis, of all of the 6,537,779 shares of Series A Common Stock issued to Geron
pursuant to the Asset Contribution Agreement, other than with respect to
fractional shares and shares that would have otherwise been distributed to Geron
stockholders residing in jurisdictions other than Distribution Jurisdictions,
which shares (totaling 263,483 shares of Series A Common Stock), as required by
the Asset Contribution Agreement, were sold at prevailing market prices with the
net cash proceeds of approximately $587,000 therefrom distributed ratably to the
stockholders who would otherwise have been entitled to receive such shares on
August 19, 2014.</FONT></P>
<P align=left><B><FONT face="Times New Roman">Item 5 - Interest in Securities of
the Issuer </FONT></B></P>
<P align=left><FONT face="Times New Roman" size=2>Item 5 of the Geron Schedule
13D is hereby amended and supplemented as follows: </FONT></P>
<P align=left><FONT face="Times New Roman" size=2>(a)-(b): The responses of the
Reporting Person to rows (7) through (13) of the second page of this Amendment
are incorporated herein by reference. Except as a result of the Series A
Distribution, to the knowledge of the Reporting Person, none of the persons
listed on Schedule I to this Amendment beneficially owns any shares of
Series A Common Stock.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>(c): Except as set forth in
Item 4 of this Amendment, neither the Reporting Person nor, to the knowledge of
the Reporting Person, any of the persons listed on Schedule I to this Amendment, has effected any transaction in the Series A Common Stock during
the past 60 days.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>(d): Not
applicable.</FONT></P>
<P align=left><FONT face="Times New Roman" size=2>(e): August 15,
2014.</FONT></P>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><B><FONT face="Times New Roman">SIGNATURE</FONT></B></P>
<P align=left>&nbsp;&nbsp;&nbsp;&nbsp; <FONT face="Times New Roman" size=2>After
reasonable inquiry and to the best of my knowledge and belief, I certify that
the information set forth in this statement is true, complete and correct.
</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="50%" colSpan=3><FONT face="Times New Roman" size=2>GERON CORPORATION</FONT></TD></TR>
  <TR>
    <TD width="99%" colSpan=4>&nbsp;&nbsp; </TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"><FONT face="Times New Roman" size=2>Date: August 19, 2014</FONT></TD>
    <TD noWrap align=left width="1%"><FONT face="Times New Roman" size=2>By:&nbsp; </FONT></TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="29%"><FONT face="Times New Roman" size=2>/s/ Olivia Bloom</FONT></TD>
    <TD noWrap align=left width="20%">&nbsp;</TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%">&nbsp;</TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Executive Vice President, Finance,</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="49%"></TD>
    <TD noWrap align=left width="1%"></TD>
    <TD noWrap align=left width="49%" colSpan=2><FONT face="Times New Roman" size=2>Chief Financial Officer and
Treasurer</FONT></TD></TR></TABLE><BR>
<HR align=center width="100%" noShade SIZE=2>

<DIV style="PAGE-BREAK-BEFORE: always"></DIV><BR>
<P align=center><U><FONT face="Times New Roman" size=2>SCHEDULE
I</FONT></U><FONT face="Times New Roman" size=2> </FONT><FONT face="Times New Roman"></FONT></P>
<P align=center><B><FONT face="Times New Roman" size=2>DIRECTORS AND EXECUTIVE
OFFICERS OF GERON CORPORATION </FONT></B><FONT face="Times New Roman"></FONT></P>
<P align=left><FONT face="Times New Roman" size=2>The name and present principal
occupation of each director and executive officer of Geron Corporation are set
forth below. Unless otherwise indicated, the business address for each named
person is: c/o Geron Corporation, 149 Commonwealth Drive, Suite 2070, Menlo
Park, California 94025.</FONT></P>
<TABLE style="LINE-HEIGHT: 14pt; BORDER-COLLAPSE: collapse" cellSpacing=0 cellPadding=0 width="100%" border=0>

  <TR vAlign=bottom>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="15%"><B><FONT face="Times New Roman" size=2>Name</FONT></B></TD>
    <TD noWrap align=left width="1%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD style="BORDER-BOTTOM: #000000 1pt solid" noWrap align=left width="83%"><B><FONT face="Times New Roman" size=2>Principal Occupation or
      Employment</FONT></B></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><B><I><FONT face="Times New Roman" size=2>Directors</FONT></I></B></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Hoyoung Huh, M.D., Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Daniel M. Bradbury</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Karin Eastham</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>V. Bryan Lawlis, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>President and Chief Executive Officer, Itero
      Biopharmaceuticals LLC <SUP>(1)</SUP></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Susan M. Molineaux, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>President and Chief Executive Officer,
      Calithera Biosciences, Inc. <SUP>(2)</SUP></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Thomas Hofstaetter, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Independent Director</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff>&nbsp;</TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>President and Chief Executive
    Officer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Robert J. Spiegel, M.D., FACP</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Chief Medical Officer, PTC Therapeutics,
      Inc. <SUP>(3)</SUP></FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><B><I><FONT face="Times New Roman" size=2>Executive Officers</FONT></I></B></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>John A. Scarlett, M.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>President and Chief Executive
    Officer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Olivia K. Bloom</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Executive Vice President, Finance, Chief
      Financial Officer and Treasurer</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Andrew J. Grethlein, Ph.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Executive Vice President, Development and
      Technical Operations</FONT></TD></TR>
  <TR vAlign=bottom>
    <TD noWrap align=left width="15%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Stephen N. Rosenfield, J.D.</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#ffffff></TD>
    <TD noWrap align=left width="83%" bgColor=#ffffff><FONT face="Times New Roman" size=2>Executive Vice President, General Counsel
      and Corporate Secretary</FONT></TD></TR>
  <TR vAlign=top>
    <TD noWrap align=left width="15%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Melissa A. Kelly Behrs</FONT></TD>
    <TD noWrap align=left width="1%" bgColor=#c0c0c0></TD>
    <TD noWrap align=left width="83%" bgColor=#c0c0c0><FONT face="Times New Roman" size=2>Executive Vice President, Business Development and Portfolio &amp; Alliance Management</FONT></TD></TR></TABLE>____________________<BR>&nbsp;<BR>
<TABLE cellSpacing=0 cellPadding=0 border=0>

  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Itero
      Biopharmaceuticals LLC, a specialty biopharmaceutical company, 155 Bovet
      Road, San Mateo, CA 94402</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(2)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>Calithera
      Biosciences, Inc., an oncology therapeutics development company, 343
      Oyster Point Blvd., Suite 200 South San Francisco, CA 94080</FONT></TD></TR>
  <TR>
    <TD vAlign=top colSpan=2>&nbsp;&nbsp; </TD></TR>
  <TR>
    <TD vAlign=top noWrap><FONT face="Times New Roman" size=2>(3)</FONT></TD>
    <TD vAlign=top width="100%"><FONT face="Times New Roman" size=2>PTC
      Therapeutics, Inc., a specialty biopharmaceutical company, 100 Corporate
      Court, South Plainfield, NJ 07080-2449</FONT></TD></TR>
  <TR>
    <TD colSpan=2>&nbsp; </TD></TR></TABLE>
<HR align=center width="100%" noShade SIZE=2>

</BODY>

</HTML>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
